Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Consultant, Narayana Nethralaya, Bengaluru, Karnataka, India.
Indian J Ophthalmol. 2023 Sep;71(9):3149-3159. doi: 10.4103/IJO.IJO_228_23.
The management of an episode of corneal graft rejection (CGR) is primarily by corticosteroids. Immunomodulators are useful for long-term immunosuppression and in dealing with cases of high-risk (HR) corneal grafts. The classical signs of CGR following penetrating keratoplasty (PKP) include rejection line, anterior chamber (AC) reaction, and graft edema. However, these signs may be absent or subtle in cases of endothelial keratoplasty (EK). Prevention of an episode of graft rejection is of utmost importance as it can reduce the need for donor cornea significantly. In our previous article (IJO_2866_22), we had discussed about the immunopathogenesis of CGR. In this review article, we aim to discuss the various clinical aspects and management of CGR.
角膜移植排斥反应(CGR)的治疗主要依靠皮质类固醇。免疫调节剂对于长期免疫抑制和处理高危(HR)角膜移植非常有用。穿透性角膜移植(PKP)后 CGR 的典型表现包括排斥线、前房(AC)反应和移植物水肿。然而,在内皮角膜移植(EK)中,这些表现可能不存在或不明显。预防移植物排斥反应非常重要,因为它可以大大减少对供体角膜的需求。在我们之前的文章(IJO_2866_22)中,我们讨论了 CGR 的免疫发病机制。在这篇综述文章中,我们旨在讨论 CGR 的各种临床方面和管理。